**SABRIL** is an anti-epileptic medication that inhibits the enzyme (GABA-T) which degrades GABA. There is no direct or consistent correlation between plasma concentration and efficacy.

**Authorization:** 1) Refractory complex partial seizures in adults, after several other medications have failed and in whom the potential benefits outweigh the risk of possible vision loss (see below). 2) Infantile Spasm as monotherapy for pediatric patients 1 month-2 years of age for whom the potential benefits outweigh the risk of possible vision loss.

**Dosing:** Initiate therapy with 1g/day (500mg twice a day), increased in weekly 500mg increments to 3g/day. Doses greater than 6g/day confer no advantage.

**PRECAUTIONS:** Special restricted distribution due to risk of progressive and permanent bilateral visual field constriction (SHARE program; 1-888-45-SHARE). Visual field testing required every 3 months. Increased risk of suicidal thinking (no greater than other antiepileptic medications). Somnolence and fatigue. Anemia. Peripheral neuropathy. Weight gain.

**DRUG INTERACTIONS:** caution with CNS depressants; may decrease serum concentration of phenytoin and fosphenytoin;
REFERENCES


Revision History:
Date Reviewed/No Updates: 01.13.15 by C. Sanders, MD
Date Approved by P&T Committee: 01.27.15
Date Reviewed/No Updates: 01.26.16 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 01.26.16
Date Reviewed/No Updates: 01.24.17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 01.24.17
<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>